Effect of Preexisting Serum and Mucosal Antibody on Experimental Respiratory Syncytial Virus (RSV) Challenge and Infection of Adults. (14th May 2015)

• Record Type: Journal Article
• Authors: Bagga, Bindiya; Cehelsky, Jeffrey E.; Vaishnaw, Akshay; Wilkinson, Tom; Meyers, Rachel; Harrison, Lisa M.; Roddam, Philippa L.; Walsh, Edward E.; DeVincenzo, John P.
• Is Part Of: Journal of infectious diseases. Volume 212:Number 11(2015:Dec. 01)
• Page Start: 1719
• Page End: 1725
• Publication Date: 2015-05-14
• Subjects: respiratory syncytial virus -- vaccines -- serum antibody responses -- mucosal antibody responses -- correlates of protection; Communicable diseases -- Periodicals; Diseases -- Causes and theories of causation -- Periodicals; Medicine -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.9
• DOI: 10.1093/infdis/jiv281
• Languages: English
• ISSNs: 0022-1899

Abstract

Abstract : We studied preexisting respiratory syncytial virus (RSV)–specific serum and nasal antibodies and their correlation with infectivity, viral dynamics, and disease severity in a human experimental infection model. Higher preinoculation serum neutralizing antibody titers and nasal immunoglobulin (Ig) A predicted lower infectivity and lower measures of viral replication. However, once individuals were infected, no significant protective effect of preexisting antibodies was seen. Lack of correlation between serum and mucosal antibodies was observed, implying that they are independent co-correlates of protection against RSV infection. We suggest that protection from RSV infection is a function of a complex interplay between mucosal and serum humoral immune responses.